Abbisko Cayman Limited
和譽開曼有限責任公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2256)

VOLUNTARY ANNOUNCEMENT
ABBISKO THERAPEUTICS PRESENTS LONGER-TERM EFFICACY AND SAFETY OUTCOMES FROM PHASE III MANEUVER STUDY OF PIMICOTINIB AT CTOS 2025 ANNUAL MEETING

Abbisko Cayman Limited (the "**Company**", together with its subsidiaries, the "**Group**") hereby informs the shareholders and potential investors of the Company of the attached press release that Abbisko Therapeutics Co., Ltd. ("**Abbisko Therapeutics**"), a subsidiary of the Company, announced that the poster presentation of longer-term efficacy, safety and patient-reported outcomes from the global Phase III MANEUVER study of pimicotinib (ABSK021) in patients with tenosynovial giant cell tumour ("**TGCT**") at the Connective Tissue Oncology Society ("**CTOS**") 2025 Annual Meeting.This longer-term analysis showed that sustained treatment with pimicotinib in patients with TGCT led to continued improvements in tumor response, patient-reported outcomes including pain and function, and maintained an acceptable safety profile, reinforcing its potential for long-term use in eligible patients.

This is a voluntary announcement made by the Company. The Group cannot guarantee that ABSK021 will ultimately be successfully marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Abbisko Cayman Limited
Dr. Xu Yao-Chang
Chairman

Shanghai, November 17, 2025

As at the date of this announcement, the board of directors of the Company comprises Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Ji Jing as executive directors; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Ms. Chui Hoi Yam as independent non-executive directors.

Abbisko Therapeutics Presents Longer-Term Efficacy and Safety Outcomes from Phase III MANEUVER Study of Pimicotinib at CTOS 2025 Annual Meeting

On 17 November 2025, Abbisko Therapeutics Co. Ltd. ((“**Abbisko Therapeutics**”) announced the poster presentation of longer-term efficacy, safety and patient-reported outcomes from the global Phase III MANEUVER study of pimicotinib (ABSK021) in patients with tenosynovial giant cell tumour (“**TGCT**”) at the Connective Tissue Oncology Society (“**CTOS**”) 2025 Annual Meeting. This longer-term analysis showed that sustained treatment with pimicotinib in patients with TGCT led to continued improvements in tumor response, patient-reported outcomes including pain and function, and maintained an acceptable safety profile, reinforcing its potential for long-term use in eligible patients.

TGCT is a rare and locally aggressive tumor primarily affecting joints, tendon sheaths, and bursae with potentially devastating morbidity. TGCT is driven by overexpression of colony-stimulating factor-1 (“**CSF-1**”) in neoplastic synovial cells that leads to accumulation of colony-stimulating factor-1 receptor (“**CSF-1R**”) – expressing inflammatory cells in the tumor.

The MANEUVER study is a global, multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial consisting of three parts, designed to evaluate the efficacy and safety of pimicotinib in patients with TGCT. The primary endpoint and all key secondary endpoints were met in Part 1 at week 25, and the corresponding results were presented at the 2025 American Society of Clinical Oncology (“**ASCO**”) Annual Meeting. The primary endpoint is the objective response rate (“**ORR**”) at the end of Part 1, as assessed by blind independent review committee (“**BIRC**”) per RECIST v1.1. At Week 25, pimicotinib demonstrated a statistically significant improvement in ORR compared with placebo at Week 25 (54.0% vs 3.2%, $P < 0.0001$).

The outcomes presented at the CTOS 2025 Annual Meeting were the longer-term efficacy and safety data from the completion of Part 2 of the MANEUVER study. With a median follow-up of 14.3 months, patients who had received pimicotinib from the beginning of the study demonstrated robust and durable tumor responses. The ORR by BIRC per RECIST v1.1 increased from 54% at week 25 to 76.2% (95% CI: 63.8, 86.0), with four patients achieving complete response.

Meanwhile, the study also showed continued clinically meaningful improvements in clinical outcome assessments (“**COAs**”) related to TGCT patients’ quality of life, including range of motion, stiffness, pain, and physical function. In addition, the poster presented quality of life (“**QoL**”) benefits assessed by the EQ-5D-5L visual analog scale (“**VAS**”). Patients receiving pimicotinib treatment showed a mean QoL improvement of 7.4% from baseline at Week 25, which further increased to 13.1% at Week 73.

In addition, patients who were initially randomized to the placebo arm in Part 1 and subsequently switched to pimicotinib in Part 2 also derived clinical benefit, achieving an ORR of 64.5% at a median follow-up of 8.5 months, along with notable improvements in COAs.

In terms of safety, the median dose intensity remained high at 88.2% during treatment. Most treatment-emergent adverse events ("**TEAEs**") were Grade 1-2. No new safety signals were observed, and there was no evidence of cholestatic hepatotoxicity, drug-induced liver injury, or hair/skin hypopigmentation.

It is noteworthy that at the 2025 European Society for Medical Oncology ("**ESMO**") Congress held in October this year, Professor Xiaohui Niu from Beijing Jishuitan Hospital, the leading principal investigator ("**PI**") of MANEUVER study, presented these significant research findings in an oral presentation.

About Pimicotinib

Pimicotinib is a novel, oral, highly selective, and potent small-molecule CSF-1R inhibitor independently developed by Abbisko Therapeutics. Positive top-line results from the global Phase III MANEUVER study of pimicotinib for the treatment of TGCT were announced in November 2024. Currently, pimicotinib has been included in the priority review process by the Center for Drug Evaluation ("**CDE**") of the National Medical Products Administration ("**NMPA**") in China for the treatment of adult TGCT patients requiring systemic therapy. Pimicotinib also has been granted breakthrough therapy designation ("**BTD**") by the NMPA. In December 2023, Abbisko Therapeutics entered into an agreement with Merck KGaA, Darmstadt, Germany, pertaining to the commercial rights to pimicotinib, pursuant to which Merck KGaA, Darmstadt, Germany, is responsible for the commercialization of pimicotinib globally.

Outside of China, pimicotinib has been granted BTD by the US Food and Drug Administration ("**FDA**") and PRIME Designation by the European Medicines Agency ("**EMA**").

About Abbisko Therapeutics

Founded in April 2016, Abbisko Therapeutics Co., Ltd. is an oncology-focused biopharmaceutical company based in Shanghai that is dedicated to the discovery and development of innovative medicines to treat unmet medical needs in China and globally. The Company was established by a group of seasoned drug hunters with rich research & development and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline of innovative programs focused on precision oncology and immuno-oncology.

Please visit www.abbisko.com for more information.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.